- The European Commission designates Zogenix's (NASDAQ:ZGNX) lead product candidate ZX008 an orphan medicinal product for the treatment of a rare and severe form of childhood epilepsy called Lennox-Gastaut syndrome (LGS). Among the benefits of the designation is a 10-year period of market exclusivity for the indication, if approved.
- ZX008 is a low-dose fenfluramine. It was the "Fen" component of the anti-obesity medication Fen-phen that was withdrawn from the U.S. market in 1997 due to its association with heart valve disease. It has Orphan Drug status in the U.S. for LGS and Fast Track status for Dravet syndrome.